NASDAQ:DEPO - Depomed Stock Price, Price Target & More

$6.79 +0.11 (+1.65 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$6.79
Today's Range$6.71 - $6.9950
52-Week Range$4.31 - $12.49
Volume1.32 million shs
Average Volume1.16 million shs
Market Capitalization$424.29 million
P/E Ratio-5.39
Dividend YieldN/A
Beta1.19

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:DEPO
CUSIP24990810
Phone510-744-8000

Debt

Debt-to-Equity Ratio3.21%
Current Ratio0.74%
Quick Ratio0.70%

Price-To-Earnings

Trailing P/E Ratio-5.39
Forward P/E Ratio-6.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$380.72 million
Price / Sales1.13
Cash Flow$0.8498 per share
Price / Cash7.99
Book Value$2.69 per share
Price / Book2.52

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-102,490,000.00
Net Margins-26.92%
Return on Equity-45.19%
Return on Assets-8.39%

Miscellaneous

Employees434
Outstanding Shares63,520,000

How to Become a New Pot Stock Millionaire

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed (NASDAQ:DEPO) posted its quarterly earnings data on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.05. The specialty pharmaceutical company had revenue of $94.41 million for the quarter, compared to analyst estimates of $88.75 million. Depomed had a negative return on equity of 45.19% and a negative net margin of 26.92%. View Depomed's Earnings History.

When is Depomed's next earnings date?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Depomed.

What price target have analysts set for DEPO?

8 brokerages have issued twelve-month price targets for Depomed's stock. Their predictions range from $5.00 to $14.00. On average, they expect Depomed's stock price to reach $8.75 in the next year. View Analyst Ratings for Depomed.

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. August J. Moretti, CFO & Sr. VP (Age 67)
  • Mr. Matthew M. Gosling, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Arthur Joseph Higgins, Chief Exec. Officer, Pres and Director (Age 62)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. Relationships
  • Dr. Santosh J. Vetticaden M.D., Ph.D., Sr. VP and Chief Medical & Scientific Officer (Age 59)

Has Depomed been receiving favorable news coverage?

News stories about DEPO stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Depomed earned a daily sentiment score of 0.22 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 45.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Depomed's major shareholders?

Depomed's stock is owned by a number of of institutional and retail investors. Top institutional investors include STARBOARD VALUE LP (7.70%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

How do I buy shares of Depomed?

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of DEPO stock can currently be purchased for approximately $6.79.

How big of a company is Depomed?

Depomed has a market capitalization of $424.29 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]


MarketBeat Community Rating for Depomed (DEPO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  712
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Depomed (NASDAQ:DEPO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Depomed in the last 12 months. Their average twelve-month price target is $8.75, suggesting that the stock has a possible upside of 28.87%. The high price target for DEPO is $14.00 and the low price target for DEPO is $5.00. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.332.332.22
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.75$9.5556$11.2222$12.6667
Price Target Upside: 28.87% upside46.78% upside34.72% upside135.00% upside

Depomed (NASDAQ:DEPO) Consensus Price Target History

Price Target History for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2018MizuhoReiterated RatingBuy$9.00HighView Rating Details
3/2/2018Roth CapitalSet Price TargetBuy$10.00MediumView Rating Details
3/1/2018Piper JaffrayReiterated RatingHold$8.00MediumView Rating Details
12/7/2017Royal Bank of CanadaSet Price TargetHold$9.00MediumView Rating Details
11/10/2017UBSBoost Price TargetNeutral$6.00 -> $7.00N/AView Rating Details
11/9/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
8/8/2017Janney Montgomery ScottDowngradeBuy -> Neutral$18.00 -> $8.00HighView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Depomed (NASDAQ:DEPO) Earnings History and Estimates Chart

Earnings by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Earnings Estimates

2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14

Depomed (NASDAQ DEPO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.12N/AView Earnings Details
2/27/2018Q4 2017$0.10$0.15$88.75 million$94.41 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.12$0.14$99.11 million$95.40 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09($0.43)$100.40 million$100.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.3550$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
11/1/2010Q3 2010($0.02)$0.04ViewN/AView Earnings Details
8/5/2010Q2 2010$0.04$0.08ViewN/AView Earnings Details
4/29/2010Q1 2010($0.07)($0.07)ViewN/AView Earnings Details
3/4/2010Q4 2009($0.13)($0.07)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.06)($0.10)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.19)($0.19)ViewN/AView Earnings Details
5/4/2009Q1 2009($0.22)($0.20)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.26)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.15)($0.12)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.22)($0.03)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.16)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.40$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Depomed (NASDAQ:DEPO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Depomed (NASDAQ DEPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.27%
Institutional Ownership Percentage: 91.63%
Insider Trading History for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018Matthew M. GoslingSVPSell45,519$6.58$299,515.02View SEC Filing  
12/14/2017Arthur J. HigginsInsiderBuy75,000$8.16$612,000.00View SEC Filing  
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.0026,680View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.0073,086View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.8084,336View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00109,297View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00124,297View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.0022,879View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00137,737View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.0021,319View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.5011,396View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.009,084View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.4061,698View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Depomed (NASDAQ DEPO) News Headlines

Source:
DateHeadline
Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate CommunicationsDepomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications
finance.yahoo.com - April 20 at 5:00 PM
Depomed (DEPO) Downgraded to "Sell" at BidaskClubDepomed (DEPO) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - April 19 at 1:56 PM
Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate ...Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate ...
www.globenewswire.com - April 17 at 5:27 PM
Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals ...Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals ...
globenewswire.com - April 16 at 8:45 AM
Depomed (DEPO) Rating Lowered to Neutral at Janney Montgomery ScottDepomed (DEPO) Rating Lowered to Neutral at Janney Montgomery Scott
www.americanbankingnews.com - April 12 at 9:00 PM
Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future?
finance.yahoo.com - April 12 at 5:05 PM
Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com - April 9 at 8:59 AM
Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  
finance.yahoo.com - April 9 at 8:59 AM
Piper Jaffray Analysts Give Depomed (DEPO) a $9.00 Price TargetPiper Jaffray Analysts Give Depomed (DEPO) a $9.00 Price Target
www.americanbankingnews.com - April 7 at 12:26 PM
Form 3 DEPOMED INC For: Apr 02 Filed by: Bukofzer StanForm 3 DEPOMED INC For: Apr 02 Filed by: Bukofzer Stan
www.streetinsider.com - April 5 at 10:52 AM
Depomed Sees Unusually High Options Volume (DEPO)Depomed Sees Unusually High Options Volume (DEPO)
www.americanbankingnews.com - April 5 at 6:30 AM
When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?When Will Depomed Inc (NASDAQ:DEPO) Become Profitable?
finance.yahoo.com - April 3 at 5:04 PM
Depomed (DEPO) Names Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific OfficerDepomed (DEPO) Names Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific Officer
www.streetinsider.com - April 2 at 5:02 PM
Depomed Announces the Appointment of Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific ...Depomed Announces the Appointment of Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific ...
www.globenewswire.com - April 2 at 5:02 PM
Depomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific OfficerDepomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific Officer
finance.yahoo.com - April 2 at 5:02 PM
Depomed (DEPO) PT Lowered to $6.00Depomed (DEPO) PT Lowered to $6.00
www.americanbankingnews.com - April 1 at 11:24 AM
Depomed (DEPO) Receives Consensus Recommendation of "Hold" from BrokeragesDepomed (DEPO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 31 at 7:46 PM
Depomed Distances Itself From NucyntaDepomed Distances Itself From Nucynta
seekingalpha.com - March 27 at 9:07 AM
Depomed (DEPO) Lowered to Sell at BidaskClubDepomed (DEPO) Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Depomed (DEPO) Downgraded by ValuEngine to Strong SellDepomed (DEPO) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 25 at 6:58 PM
BidaskClub Downgrades Depomed (DEPO) to Strong SellBidaskClub Downgrades Depomed (DEPO) to Strong Sell
www.americanbankingnews.com - March 25 at 9:30 AM
Mizuho Reaffirms Buy Rating for Depomed (DEPO)Mizuho Reaffirms Buy Rating for Depomed (DEPO)
www.americanbankingnews.com - March 23 at 1:30 PM
Depomed Announces New Corporate Headquarters - GlobeNewswire (press release)Depomed Announces New Corporate Headquarters - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:42 AM
Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisisDrug stocks dive as Trump says he's considering suing drugmakers over opioid crisis
finance.yahoo.com - March 20 at 4:52 PM
Drug stocks dive as Trump says hes considering suing drugmakers over opioid crisisDrug stocks dive as Trump says he's considering suing drugmakers over opioid crisis
finance.yahoo.com - March 19 at 4:51 PM
Depomed Announces New Corporate HeadquartersDepomed Announces New Corporate Headquarters
finance.yahoo.com - March 19 at 8:56 AM
Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)?Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)?
finance.yahoo.com - March 16 at 8:56 AM
Global Pain Management Therapeutics Market Opportunities 2018: Mallinckrodt Pharmaceuticals, Pfizer, Purdue Pharma L.P, Novartis AGGlobal Pain Management Therapeutics Market Opportunities 2018: Mallinckrodt Pharmaceuticals, Pfizer, Purdue Pharma L.P, Novartis AG
www.marketwatch.com - March 14 at 9:24 AM
Form 4 DEPOMED INC For: Mar 07 Filed by: Gosling Matthew MForm 4 DEPOMED INC For: Mar 07 Filed by: Gosling Matthew M
www.streetinsider.com - March 10 at 8:50 AM
Matthew M. Gosling Sells 45,519 Shares of Depomed Inc (DEPO) StockMatthew M. Gosling Sells 45,519 Shares of Depomed Inc (DEPO) Stock
www.americanbankingnews.com - March 9 at 9:28 PM
PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/YPDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y
www.msn.com - March 9 at 6:12 PM
Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoes Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - March 9 at 9:05 AM
Exploring Depomed’s Financial Performance TodayExploring Depomed’s Financial Performance Today
finance.yahoo.com - March 8 at 8:58 AM
Inside Depomed’s Portfolio: The Key DrugsInside Depomed’s Portfolio: The Key Drugs
finance.yahoo.com - March 7 at 5:56 PM
Depomed Inc (DEPO) Receives Consensus Rating of "Hold" from AnalystsDepomed Inc (DEPO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 6 at 7:36 PM
Depomed to Present at Healthcare Conferences in MarchDepomed to Present at Healthcare Conferences in March
finance.yahoo.com - March 6 at 5:18 PM
What this East Bay company is saving — and losing — by moving to the Midwest - San Francisco Business TimesWhat this East Bay company is saving — and losing — by moving to the Midwest - San Francisco Business Times
www.bizjournals.com - March 4 at 8:48 AM
Depomed (DEPO) Given a $10.00 Price Target at Roth CapitalDepomed (DEPO) Given a $10.00 Price Target at Roth Capital
www.americanbankingnews.com - March 3 at 5:38 PM
Bogle Investment Management L P DE Has $8.13 Million Holdings in Depomed Inc (DEPO)Bogle Investment Management L P DE Has $8.13 Million Holdings in Depomed Inc (DEPO)
www.americanbankingnews.com - March 3 at 4:52 AM
Depomed (DEPO) Receives Hold Rating from Piper Jaffray CompaniesDepomed (DEPO) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - March 1 at 8:13 PM
Depomed Sees Unusually Large Options Volume (DEPO)Depomed Sees Unusually Large Options Volume (DEPO)
www.americanbankingnews.com - March 1 at 7:24 AM
Here's Why Depomed Inc Fell as Much as 13.8% TodayHere's Why Depomed Inc Fell as Much as 13.8% Today
finance.yahoo.com - February 28 at 5:35 PM
Depomed (DEPO) Issues Quarterly  Earnings Results, Beats Estimates By $0.05 EPSDepomed (DEPO) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - February 28 at 11:16 AM
BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52
www.reuters.com - February 27 at 5:31 PM
Depomed, Inc. to Host Earnings CallDepomed, Inc. to Host Earnings Call
finance.yahoo.com - February 27 at 5:31 PM
Depomed reports 4Q lossDepomed reports 4Q loss
finance.yahoo.com - February 27 at 5:31 PM
State of Wisconsin Investment Board Boosts Holdings in Depomed Inc (DEPO)State of Wisconsin Investment Board Boosts Holdings in Depomed Inc (DEPO)
www.americanbankingnews.com - February 27 at 3:45 PM
Systematic Financial Management LP Has $1.83 Million Stake in Depomed Inc (DEPO)Systematic Financial Management LP Has $1.83 Million Stake in Depomed Inc (DEPO)
www.americanbankingnews.com - February 25 at 11:30 AM
Depomed (DEPO) Scheduled to Post Earnings on TuesdayDepomed (DEPO) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 22 at 8:16 PM
Depomed (DEPO) Upgraded by BidaskClub to HoldDepomed (DEPO) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - February 21 at 6:26 AM

SEC Filings

Depomed (NASDAQ:DEPO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Depomed (NASDAQ:DEPO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Depomed (NASDAQ DEPO) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.